‘There Are Signs That a Market Bottom Is in Sight’: Oppenheimer Likes These 2 Stocks for a Comeback Rally

S&P Futures



Dow Futures



Nasdaq Futures



Russell 2000 Futures



Crude Oil












10-Yr Bond















CMC Crypto 200



FTSE 100



Nikkei 225



The big question: Has the market hit a bottom yet? Well, according to Oppenheimer’s Head of Technical Analysis Ari Wald, there are signs one is forming, the most notable of which is that the Russell 2000 index – the barometer for small-cap stocks – “held to the June lows in the most recent late Q3 move to the downside.”

Wald also notes that the signal of a market top is when the S&P 500 makes a “higher high, and small caps make a lower high,” and we are currently seeing the opposite scenario play out which might point to a market bottom.

Whether Wald is right or not remains to be seen, but in the meantime his analyst colleagues at Oppenheimer have noted 2 names which they think are well-positioned to push higher from here. We ran the tickers through the TipRanks platform to see what the rest of the Street has in mind for them. Let’s take a closer look.

Corebridge Financial, Inc. (CRBG)

We’ll start with Corebridge, a financial services and insurance products provider based in Texas. Its main offerings include Individual Retirement, Group Retirement, Life Insurance and Institutional Markets.

Many stocks have collapsed in 2022 but Corebridge has managed to sidestep the bear market. That, however, is entirely down to the fact this name is a stock market newbie. In September, Corebridge raised $1.68 billion, in what was the year’s biggest U.S. IPO, after being spun out from parent company AIG (the proceeds went directly to AIG).

While the company has yet to report any quarterly financial statements as a public entity, it should be noted that with more than $350 billion in assets under management, it is one of the biggest providers of retirement financial products, and a highly profitable one at that; in the first six months of the year, Corebridge generated revenues of $15.7 billion, while profit more than doubled from the same period a year ago to $6.4 billion.

In his initiation note, Oppenheimer analyst Chris Kotowski highlights the “strong cash generation potential.”

“As the life insurance operation of AIG, Corebridge has in recent years delivered more than $2B annually in adjusted earnings and cash distributions to its former parent,” The 5-star analyst said. “In the future, we see that cash coming to shareholders in the form of both dividends (currently targeted at $600M annually) and share buybacks, which we would expect to commence within a few quarters. We expect about $2.4B in adjusted earnings in 2023E, and management is targeting a total return to shareholders of 60-65%, which would equate to ~$1.5B, or a double-digit cash return given the current $13.1B market capitalization, plus capital retention for future growth.”

To this end, Kotowski puts an Outperform (i.e., Buy) rating on CRBG, backed by a $30 price target. The implication for investors? Upside of 51% from current levels. (To watch Kotowski’s track record, click here)

Overall, this new stock has a Moderate Buy rating from the analyst consensus, after attracting 12 reviews since the IPO. These reviews break down 8 to 4 in favor of the Buys over the Holds. Shares in CRBG are selling for $19.81 and the stock’s $24.83 average price target suggests it has room for 25% upside potential in the next 12 months. (See CRBG stock forecast on TipRanks)

POINT Biopharma Global (PNT)

The next stock we’ll look at is POINT Biopharma, a researcher in the field of radiopharmaceutical drug development and evaluation. Radiopharmaceutical therapy is an approach which uses radiation to target specific cancer cells with minimal impact on otherwise healthy cells. As such, the company is focused on developing and bringing to market radioligands that take the good fight to cancer.

POINT has several candidates in the early-stages of development, including potential pan-cancer target PNT2004, a best-in-class FAP-? targeted radioligand.

The company also has two late-stage programs in progress. One is for PNT2003, a somatostatin receptor (SSTR) targeted radioligand therapy being developed to treat patients with SSTR-positive neuroendocrine tumors. Its trial is now fully enrolled, and a data readout is expected later this year.

The other asset on the radar right now is PNT2002, currently being assessed in the Phase 3 SPLASH study and indicated as a treatment for metastatic castration-resistant prostate cancer (mCRPC). In the U.S., 52,000 men are either diagnosed with or progress to mCRPC each year. The company recently presented early positive data from the study.

Among the bulls is Oppenheimer analyst Jeff Jones who thinks the future is bright for this biotech.

“We see PNT as a leader in the radiopharmaceutical therapeutics (RPT) space based on: 1) deep pipeline, with two late-stage clinical programs–PNT2002 in PSMA + metastatic castration resistant prostate cancer (mCRPC) and PNT2003 in neuro-endocrine tumors (NETs)–each targeted for launch in 2025; 2) a robust supply-chain foundation which we see as critical for success in the RPT space; and 3) platform technology that may provide substantial differentiation for future drug candidates. PNT’s >$300M in cash, inclusive of its latest financing, supports operations through 2024E, positioning PNT for significant clinical read-outs, pipeline maturation, and commercial launch preparations,” Jones wrote.

POINT shares have bucked the trend for widespread losses in 2022 and even after a recent public offering of common stock sent shares lower, they are still up 38% since the turn of the year.

Jones evidently thinks there’s plenty of room left to run. Along with initiating coverage with an Outperform (i.e., Buy) rating, the analyst’s $20 price target implies shares will be changing hands for a 158% premium a year from now. (To watch Jones’ track record, click here)

All in all, some stocks make a roundly positive impression on Wall Street’s analysts, and PNT is one of those. This radiopharmaceutical researcher has a unanimous Strong Buy consensus rating, based on 7 recent positive reviews. The shares are priced at $7.74 and the average price target is even a touch higher than Jones would allow. At $20.43, it suggests that PNT shares can appreciate ~164% in the coming 12 months. (See PNT stock forecast on TipRanks)

To find good ideas for stocks trading at attractive valuations, visit TipRanks’ Best Stocks to Buy, a newly launched tool that unites all of TipRanks’ equity insights.

Disclaimer: The opinions expressed in this article are solely those of the featured analyst. The content is intended to be used for informational purposes only. It is very important to do your own analysis before making any investment.



Jim Cramer Says Stocks Will Climb Once Fed Signals Shift; Here Are 2 Names to Watch

Inflation is high, the Fed is aggressively hiking interest rates, and the markets keep testing their lows for the year. The rest of this week will see several key monthly reports, including the consumer price index, or the inflation report, on Thursday. Currently, inflation is up 8.3% since last year, and economists are expecting that number to decline to 8.1%. Jim Cramer, the well-known host of CNBC’s ‘Mad Money’ program, is finding a silver lining in the current situation, telling investors, “


Ray Dalio Says There’s a ‘Perfect Storm’ Brewing; Here Are 2 High-Yield Dividend Stocks to Protect Your Portfolio

The headwinds have piled up for the US economy, and today’s producer price index, coming in well above the forecasts, was just the latest blow. As the PPI reminds us, inflation is stubbornly high, and compounding on last year’s elevated numbers. In addition, we’re facing a 1H GDP contraction, a nosedive in consumer confidence, shaky supplies chains, and the Federal Reserve’s rapid shift to hiking interest rates. And all of that may just be the tip of the iceberg. Billionaire investor Ray Dalio s


BlackRock profit beats as ETF demand holds up against market rout

The threat of a recession, rapidly rising interest rates and the Ukraine crisis have slammed both bonds and stocks this year, keeping investors on the back foot in a blow to businesses such as BlackRock. The company’s assets under management (AUM) dropped 16% year-on-year to $7.96 trillion in the third quarter as a stronger dollar also piled on pressure by dampening the value of investments in key European and Asian markets. That still surpassed analysts’ expectations of $7.07 per share, according to IBES data from Refinitiv, as BlackRock managed to partially offset the market downturn thanks to its diversified business model spearheaded by iShares ETFs.

Motley Fool

1 Stock-Split Stock to Buy Hand Over Fist and 1 to Avoid Like the Plague

The benchmark S&P 500, which is typically viewed as the most encompassing barometer of stock market health, delivered its worst first-half return since Richard Nixon was president. The Dow Jones Industrial Average and Nasdaq Composite haven’t fared any better, with both indexes mired in a bear market. A “stock split” is a mechanism that allows a publicly traded company to alter its share price and outstanding share count without affecting its market cap or operations.


Bridgewater’s Dalio warns of a ‘perfect storm’ for economy

Ray Dalio, the billionaire investor who built Bridgewater Associates into one of the world’s biggest hedge funds, said a “perfect storm” is forming that will spread economic pain as the U.S. Federal Reserve raises interest rates. “I don’t know whether that’s 4.5% or the economy could not take an interest rate much higher than that before it’s going to be negative.”

Yahoo Finance Video

Apple withholds new perks from unionized stores, Amazon workers prepare for union elections

Tech reporter Allie Garfinkle details the beginning of union elections for Amazon workers in Albany and California warehouse workers’ petition for a union election, in addition to how Apple is withholding new education and health perks from workers at unionized stores.

Yahoo Finance

The 517-hp Polestar 3 EV SUV will be built in America

Polestar officially took the wraps off its latest creation, the Polestar 3 electric SUV. The stats are quite impressive, but what’s even more intriguing is where the Polestar 3 will be made.
“Polestar 3 is a powerful electric SUV that appeals to the senses with a distinct, Scandinavian design and excellent driving dynamics,” said Polestar CEO Thomas Ingenlath in a statement. “It takes our manufacturing footprint to the next level, bringing Polestar production to the United States. We are proud and excited to expand our portfolio as we continue our rapid growth.”


TSMC Cuts Capital Spending 10% in a Warning for Tech Sector

(Bloomberg) — Taiwan Semiconductor Manufacturing Co. slashed its 2022 capital spending target by roughly 10%, a dramatic sign of trouble for the technology industry from the world’s most valuable chip company.Most Read from BloombergIntel Is Planning Thousands of Job Cuts in Face of PC SlumpHere’s How Weird Things Are Getting in the Housing MarketPutin Says All Infrastructure at Risk After Nord Stream HitAlex Jones Must Pay $965 Million for His Sandy Hook LiesTSMC said it expects to spend about


Taiwan Semi reports stronger-than-forecast profit

Third-party silicon-wafer manufacturer reported Taiwan Semiconductor Manufacturing Co. reported a stronger-than-forecast 19% increase in profit for the third quarter.

Leave a Reply

Your email address will not be published. Required fields are marked *